Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases (Including Pediatric Inflammatory Multisystemic Syndromes Related to Covid 19, Kawasaki Disease and Myocarditis)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myocarditis
- Sponsor
- Central Hospital, Nancy, France
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- need of hemodynamic support
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS).
These 3 inflammatory cardiac diseases have clinical, biological, and echographic similarities and differences. Nevertheless their modalities of monitoring, management and evolution are different. The investigators wish to retrospectively analyze biological and echocardiographic data of Kawasaki disease, myocarditis, PIMS patients managed at Nancy Children Hospital from January 1, 2017 to June 31, 2023.
The primary objective of this study is to identify, for these 3 pathologies, the prognostic factors of initiation of inotropic support.
The secondary objective is to identify the prognostic factors of degradation of ventricular function.
Investigators
BOSSER Gilles
chief of congenital and pediatric cardiology department
Central Hospital, Nancy, France
Eligibility Criteria
Inclusion Criteria
- •diagnostic of PIMS, myocarditis or kawasaki disease patients
- •age \< 18 years
Exclusion Criteria
- •uncertain diagnosis
- •other complex heart disease
- •management out of Nancy University children hospital center
Outcomes
Primary Outcomes
need of hemodynamic support
Time Frame: up to 20 days
The need for haemodynamic support is defined dichotomously: yes or no. The investigators wish to identify the predictive factors of need for haemodynamic support among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction, global and regional longitudinal strain at admission (in %)).
Secondary Outcomes
- deterioration of Left Ventricular Ejection fraction(up to 20 days)